MILWAUKEE & NEWTON, Mass. — Versiti Clinical Trials Services announced a partnership with 4D Path aimed at accelerating the development of personalized cancer treatments through advanced biomarker technology.
The collaboration will make 4D Path’s Q-Plasia OncoReader platform available to pharmaceutical companies and clinical research organizations working with Versiti, providing new tools to analyze how individual tumors respond to treatment.
The platform uses artificial intelligence to convert routine biopsy images into predictive biomarkers that reveal interactions between tumors and the immune system. According to the companies, the technology delivers results faster and at lower cost than traditional methods, enabling researchers to make earlier and more informed decisions during drug development.
“Every day matters when we’re developing treatments that could save lives,” said Chris Miskel, president and CEO of Versiti. “This partnership gives our clients the speed and precision they need to bring personalized cancer therapies to patients who can no longer wait. We’re seeing a deeper understanding of how individual cancers behave, with unprecedented clarity that wasn’t possible before.”
The companies said the platform can be applied across multiple cancer types and produces consistent, reproducible results designed to meet regulatory standards. The approach is intended to provide clinically relevant insights while reducing complexity in the research process.
“VCTS shares our commitment to making precision medicine accessible and practical,” said Tathagata Dasgupta, founder, president, and chief technology officer of 4D Path. “Together, we’re giving researchers the clarity and insights they need to develop better treatments faster, without special processing or added complexity.”
Versiti said the partnership expands its oncology clinical trial capabilities by combining trial management services with new analytical tools aimed at improving outcomes and speeding development timelines.
